DOCSLIB.ORG

Self-Administration of Abused Substances: Methods for Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Self-Administration of Abused Substances: Methods for Study Self-Administration of Abused Substances: Methods for Study U.S. DEPARTMENT OF HEALTH, EDUCATION AND WELFARE Public Health Service Alcohol, Drug Abuse, and Mental Health Administration Self-Administration of Abused Substances: Methods for Study Editor: Norman A. Krasnegor, Ph.D. NIDA Research Monograph 20 July 1978 DEPARTMENT OF HEALTH. EDUCATION, AND WELFARE Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents U.S. Government Printing Office, Washington, D.C. 20402 Stock No. 017-024-00794-3 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical re- views of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Polo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Department of Psychology. UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHEW Washington, D C Lee Robins, Ph.D. Washington University School of Medicine St Louis, Missouri NIDA Research Monograph series William Pollin, M.D. DIRECTOR, NIDA Marvin Snyder, Ph.D. ACTING DIRECTOR, DIVISION OF RESEARCH, NIDA Robert C. Petersen, Ph.D. EDITOR-IN-CHIEF Eleanor W. Waldrop MANAGING EDITOR Parklawn Building. 5600 Fishers Lane, Rockville, Maryland 20857 Self-Administration of Abused Substances: Methods for Study ACKNOWLEDGMENTS This monograph is based on papers presented at a tech- nical review conducted by Plog Research, Inc., Reseda, California, under NIDA Contract No. 271-77-3413. The conference took place on February 14 and 15, 1978, in Reston, Virginia. Library of Congress catalog card number 78-63094 NIDA Research Monographs are indexed in the Index Medicus. They are selectively included in the coverage of BioSciences Information Service, Chemical Abstracts, Psychological Abstracts, and Psychopharmacological Abstracts. DHEW Publication No. (ADM) 80-727 Formerly DHEW Publication No. (ADM) 78-727 Printed 1978 Reprinted 1979 iv Foreword In July of 1975, the National Institute on Drug Abuse held a con- ference on the possible commonalities inherent in four substance use patterns : cigarette smoking, alcohol drinking, excessive caloric intake, and illicit drug use. The consensus of the conferees was that there may be a set of basic processes which underlie these four behaviors and that the scientific evidence may be available and accessible if the data on each of these patterns are assessed within a broad framework. By widening the perspective, it is hoped that features common to substance abuse behavior can be discovered from the gestalt of this generic approach. While it is clear that there are numerous ways to conceptualize and study substance abuse behavior (e.g., psychodynamics, person- ality theory, etc.), the papers in this volume focus upon meth- odological approaches used to study self-administration of abused substances by humans under controlled laboratory conditions. This unique monograph illustrates the convergence of techniques used by behavioral scientists working in this area of inquiry and can serve as a point of reference for others who wish to conduct similar research. William Pollin, M.D. Director National Institute on Drug Abuse v Technical Review Participants Thomas F. Babor, Ph.D. Jerome II. Jaffe, M.D. Research Psychologist Professor of Psychiatry Alcohol and Drug Abuse Research College of Physicians and Surgeons Center Columbia University The McLean Hospital 422 West 168th Street Belmont, Massachusetts 02178 New York, New York 10032 George E. Bigelow, Ph.D. Murray E. Jarvik, M.D. Department of Psychiatry Professor of Psychiatry Baltimore City Hospital and Pharmacology Baltimore, Maryland 21224 University of California School of Medicine Marian W. Fischman, Ph.D. Neuropsychiatric Institute University of Chicago The Center for the Health Sciences Department of Psychiatry 650 Westwood Plaza Box 411 Los Angeles, California 90024 950 East 59th Street Chicago, Illinois 60637 Reese T. Jones, M.D. Department of Psychiatry Marshal F. Folstein M.D. University of California Department of Psychiatry and San Francisco, California 94143 Behavioral Sciences The Johns Hopkins Hospital Maureen B. Kanzler, Ph.D. Baltimore, Maryland 21205 Department of Biological Psychiatry New York State Psychiatric Roland R. Griffiths, Ph.D. Institute Department of Psychiatry and 722 West 168th Street Behavioral Sciences New York, New York 10032 The Johns Hopkins University School of Medicine Ira Liebson, M.D. Baltimore, Maryland 21205 City of Baltimore Department of Hospitals Ellen R. Gritz, Ph.D. 4940 Eastern Avenue University of California Baltimore, Maryland 21224 Department of Psychiatry School of Medicine Richard Marcus, Ph.D. Neuropsychiatric Institute Research Psychologist 650 Westwood Plaza National Institute on Alcohol and Los Angeles, California 90024 Alcohol Abuse 5600 Fishers Lane Leonard Heston, M.D. Rockville, Maryland 20857 University of Minnesota Department of Psychiatry Paul R. McHugh, M.D. Research Unit Chairman and Psychiatrist-in-Chief Medical School, Box 392 Department of Psychiatry and Mayo Memorial Building Behavioral Sciences 420 Delaware Street, S.E. The Johns Hopkins University Minneapolis, Minnesota 55455 School of Medicine Baltimore, Maryland 21205 vi Nancy K. Mello, Ph.D. Eberhard H. Uhlenhuth, M.D. Associate Professor The University of Chicago of Psychology Department of Psychiatry Alcohol and Drug Abuse Research 950 East 59th Street Center Chicago, Illinois 60637 The McLean Hospital Harvard Medical School Orland W. Wooley, Ph.D. Belmont, Massachusetts 02178 Department of Psychiatry University of Cincinnati Jack H. Mendelson, M.D. College of Medicine Building Professor of Psychiatry 231 Bethesda Avenue Alcohol and Drug Abuse Research Cincinnati, Ohio 45267 Center The McLean Hospital Susan C. Wooley, Ph.D. Harvard Medical School Department of Psychiatry Belmont, Massachusetts 02178 University of Cincinnati College of Medicine Building Roy W. Pickens, Ph.D. 231 Bethesda Avenue University of Minnesota Cincinnati, Ohio 45267 Department of Psychiatry, Research Unit Medical School Conference Moderator 420 Delaware Street, S.E. Minneapolis, Minnesota 55455 Norman A. Krasnegor, Ph.D. Division of Research Charles R. Schuster, Ph.D. National Institute on Drug Abuse Professor of Psychiatry and 5600 Fishers lane Pharmacological and Physio- Rockville, Maryland 20857 logical Sciences The University of Chicago Department of Psychiatry 950 East 59th Street Chicago, Illinois 60037 Harlan Shannon, Ph.D. The NIDA Addiction Research Center P.O. Box 12390 Lexington, Kentucky 40583 Maxine Stitzer, Ph.D. Behavioral Pharmacology Research Unit Department of Psychiatry D Building 5 West Baltimore City Hospitals 4940 Eastern Avenue Baltimore, Maryland 21224 vii Contents Foreword William Pollin . v Technical Review Participants . , . vi Chapter 1 Introduction and Implications Norman A. Krasnegor . i I. DRUGS AND ETHANOL Chapter 2 Drug Seeking: A Behavioral Analysis in Animals and Humans Marian W. Fischman and Charles R. Schuster . 4 Chapter 3 Experimental Drug Self-Administration: Generality Across Species and Type of Drug Roland R. Griffiths, George R. Bigelow, and Ira Liebson . 24 Chapter 4 Therapeutic Self-Medication as a Context for Drug Abuse Research George E. Bigelow, Ira Liebson, Julia Kaliszak, and Roland R. Griffiths . 44 Chapter 5 Drug Abuse Research in Outpatient Clinics Maxine Stitzer and George E. Bigelow . 59 Chapter 6 Drug Self-Administration in Humans Chris E. Johanson and Eberhard H. Uhlenhuth . 68 Chapter 7 Experimental Studies of Sedative Self-Administration by Humans Roy W. Pickens and Leonard L. Heston . 86 Chapter 8 Marihuana, Alcohol, and Polydrug Use: Human Self-Administration Studies Nancy K. Mello and Jack H. Mendelson . 93 Chapter 9 Heroin Self-Administration: An Operant Analysis Jack H. Mendelson and Nancy K. Mello . 128 Chapter 10 Studying Social Reactions to Drug Self- Administration Thomas F. Babor . 149 viii II. FOOD AND TOBACCO Chapter 11 Defective Long-Term Caloric Regulation in Obesity Marshal F. Folstein and Paul R. McHugh . 182 Chapter 12 Methods and Findings in Study of Food Regulation in Obesity Susan C. Wooley and Orland W. Wooley . 189 Chapter 13 Tobacco Smoking and Nicotine Tolerance Reese T. Jones, Thomas R. Farrell III, Ronald I. Herning . 202 Chapter 14 Tobacco and Nicotine Self-Administration in Humans: The Evolution of a Methodology Jerome H. Jaffe and Maureen B. Kanzler . 209 Chapter 15 Patterns of Puffing in Cigarette Smokers Ellen R. Gritz . 221 Chapter 16 Self-Administration of Cigarettes With Varying Tobacco and Nicotine Content Murray E. Jarvik . 236 List of Monographs . 244 ix Chapter 1 Introduction and Implications Norman A. Krasnegor, Ph.D. This monograph is the first in a series of related volumes which will address different aspects of an
Load more

Recommended publications
  • Cerebellar Toxicity of Phencyclidine
    The Journal of Neuroscience, March 1995, 75(3): 2097-2108 Cerebellar Toxicity of Phencyclidine Riitta N&kki, Jari Koistinaho, Frank Ft. Sharp, and Stephen M. Sagar Department of Neurology, University of California, and Veterans Affairs Medical Center, San Francisco, California 94121 Phencyclidine (PCP), clizocilpine maleate (MK801), and oth- Phencyclidine (PCP), dizocilpine maleate (MK801), and other er NMDA antagonists are toxic to neurons in the posterior NMDA receptor antagonistshave attracted increasing attention cingulate and retrosplenial cortex. To determine if addition- becauseof their therapeutic potential. These drugs have neuro- al neurons are damaged, the distribution of microglial ac- protective properties in animal studies of focal brain ischemia, tivation and 70 kDa heat shock protein (HSP70) induction where excitotoxicity is proposedto be an important mechanism was studied following the administration of PCP and of neuronal cell death (Dalkara et al., 1990; Martinez-Arizala et MK801 to rats. PCP (10-50 mg/kg) induced microglial ac- al., 1990). Moreover, NMDA antagonists decrease neuronal tivation and neuronal HSP70 mRNA and protein expression damage and dysfunction in other pathological conditions, in- in the posterior cingulate and retrosplenial cortex. In ad- cluding hypoglycemia (Nellgard and Wieloch, 1992) and pro- dition, coronal sections of the cerebellar vermis of PCP (50 longed seizures(Church and Lodge, 1990; Faingold et al., 1993). mg/kg) treated rats contained vertical stripes of activated However, NMDA antagonists are toxic to certain neuronal microglial in the molecular layer. In the sagittal plane, the populations in the brain. Olney et al. (1989) demonstratedthat microglial activation occurred in irregularly shaped patch- the noncompetitive NMDA antagonists,PCP, MK801, and ke- es, suggesting damage to Purkinje cells.
    [Show full text]
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence
    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
    [Show full text]
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • Pharmacological Profile of Dizocilpine (Mk-801) And€Its
    Mil. Med. Sci. Lett. (Voj. Zdrav. Listy) 2019, 88(4), 166-179 ISSN 0372-7025 (Print) ISSN 2571-113X (Online) DOI: 10.31482/mmsl.2019.019 Since 1925 PŘEHLEDOVÝ ČLÁNEK / REVIEW ARTICLE FARMAKOLOGICKÝ PROFIL DIZOCILPINU (MK-801) A MOŽNOSTI JEHO VYUŽITÍ VE ZVÍŘECÍCH MODELECH SCHIZOFRENIE PHARMACOLOGICAL PROFILE OF DIZOCILPINE (MK-801) AND ITS POTENTIAL USE IN ANIMAL MODEL OF SCHIZOPHRENIA Jan Konečný 1,2, Radomír Jůza 3, Ondřej Soukup 1,2, Jan Korábečný 1,2,3 1 Katedra toxikologie a vojenské farmacie, Fakulta vojenského zdravotnictví, Třebešská 1575, 500 02, Hradec Králové, Česká republika 2 Centrum biomedicínského výzkumu, Fakultní nemocnice Hradec Králové, Sokolská 581, 500 05 Hradec Králové, Česká republika 3 Národní ústav duševního zdraví, Topolová 748, 250 67 Klecany, Česká republika Přijato 19. července 2019. Akceptováno 5. září 2019. Zveřejněno 6. prosince 2019. Souhrn N-Methyl-D-aspartátový (NMDA) receptor patří do skupiny glutamátových receptorů, které se dále dělí na ionotropní a metabotropní. V CNS má vliv na synaptickou plasticitu a rozvoj neuronálních synapsí. Ionotropní NMDA receptory jsou aktivovány glutamátem, díky čemuž proudí pozitivně nabité ionty skrz membránu po svém koncentračním gradientu. Nicméně nadměrné hladiny glutamátu působí excitotoxicky díky vysokým intracelulárním hladinám Ca2+ a mohou vést k buněčné smrti neuronů pozorované např. u neurodegenerativních onemocnění. Antagonisté NMDA receptorů, mezi které patří například dizocilpin, ovlivňují prostupnost NMDA receptoru a zamezují tak vstupu iontů Ca2+ do buňky. Dizocilpin působí jako nekompetitivní antagonista NMDA receptoru, má antikonvulzivní a anestetické účinky. Jeho terapeutické použití u lidí není vhodné z důvodu výskytu četných vedlejších účinků, experimentálně je však využíván jako farmakologicky indukovaný animální model schizofrenie.
    [Show full text]
  • Phencyclidine: an Update
    Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • (Ph OH N N Me O YO O YO
    US 20070265293A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0265293 A1 Boyd et al. (43) Pub. Date: Nov. 15, 2007 (54) (S)-N-METHYLNALTREXONE Publication Classification (76) Inventors: Thomas A. Boyd, Grandview, NY (51) Int. Cl. (US); Howard Wagoner, Warwick, NY A6II 3L/4355 (2006.01) (US); Suketu P. Sanghvi, Kendall Park, A6M II/00 (2006.01) NJ (US); Christopher Verbicky, A6M I5/08 (2006.01) Broadalbin, NY (US); Stephen 39t. 35O C Andruski, Clifton Park, NY (US) (2006.01) A6IP 3L/00 (2006.01) Correspondence Address: St. 4. CR WOLF GREENFIELD & SACKS, P.C. (2006.01) 6OO ATLANTIC AVENUE 3G (i. 308: BOSTON, MA 02210-2206 (US) A6IP 33/02 (2006.01) C07D 489/00 (2006.01) (21) Appl. No.: 11/441,452 (52) U.S. Cl. .............. 514/282; 128/200.23; 128/202.17; (22) Filed: May 25, 2006 546/45 Related U.S. Application Data (57) ABSTRACT This invention relates to S-MNTX, methods of producing (60) Provisional application No. 60/684,570, filed on May S-MNTX, pharmaceutical preparations comprising 25, 2005. S-MNTX and methods for their use. O G M Br Br e (pH OH N N Me O YO O YO OH OH R-MNTX S-MNTX Patent Application Publication Nov. 15, 2007 Sheet 1 of 6 US 2007/0265293 A1 Fig. 1 OH OH Me-N Me-N D / O O -----BBr, O O CHCI NMP, 3 AUTOCLAVE, 70'C OMe OH 1 2 Br OH As GE) G As 69 GOH Me-N ION Me-N -lass O SO EXCHANGE O SO OH OH 3 S-MNTX 1 - OXYCODONE 2 - OXYMORPHONE 3 - ODIDE SALT OF S-MNTX Fig.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • Symposium Iv. Discriminative Stimulus Effects
    Life Sciences, Vol. 28, pp. 1571-1584 Pergamon Press Printed in the U.S.A. MINI - SYMPOSIUM IV. DISCRIMINATIVE STIMULUS EFFECTS OF NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED ACTIONS Seymore Herling and James H. Woods Departments of Pharmacology and Psychology University of Michigan Ann Arbor, Michigan q8109 The different pharmacological syndromes produced by morphine and related drugs in the chronic spinal dog led Martin and his colleagues (1,2) to suggest that these drugs exert their agonist actions 0y interacting with three distinct receptors (~,K, and e). Morphine was hypothesized to be an agonist for the p receptor, ketazocine (ketocyclazocine) was an agonist for the K receptor, and SKF-10,0q7 was an agonist for the ~ receptor. The effects of these three drugs in the chronic spinal dog were reversed by the narcotic antagonist, naltrexone, indicating that the effects of these drugs are narcotic agonist effects (I). In additlon to the different effects of these narcotics in the non- dependent chronic spinal dog, the effects of morphine, ketazocine, and SKF-IO,047 in several other behavioral and physiological preparations are consistent with the concept of multiple receptors. For example, while ketazocine and ethylketazocine, like morphine, produce analgesia, these compounds, unlike morphine, do not suppress signs of narcotic abstinence in the morphine-dependent rhesus monkey or morphine-dependent chronic spinal dog (1-5). Further, the characteristics of ketazocine withdrawal and antagonist- precipitated abstinence syndromes, although similar to those of cyclazocine, are quailtativeiy different from those of morphine (1,2). In rhesus monkeys, ketazocine, ethylketazocine, and SKF-10,047 maintain lever pressing at rates comparable to or below those maintained by saline, and well below response rates maintained by codeine or morphine (5,6), suggesting that the former set of drugs have limited reinforcing effect.
    [Show full text]
  • Etoxadrol-Meta-Isothiocyanate: a Potent, Enantioselective, Electrophilic Affinity Ligand for the Phencyclidine-Binding Site
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 238, number 2, 369-374 FEB 06377 October 1988 Etoxadrol-meta-isothiocyanate: a potent, enantioselective, electrophilic affinity ligand for the phencyclidine-binding site Andrew Thurkauf, Mariena V. Mattson, Philip N. Huguenin*, Kenner C. Rice and Arthur E. Jacobson Section on Drug Design and Synthesis, Laboratory of Neuroscience, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, IUD 20892, USA Received 17 August 1988 Etoxadrol-mera-isothiocyanate (2S,4S,692-ethyl-2-(3-isothiocyanatophenyl)-2-pi~ridyl)1,3-dioxolane, 4n) has been synthesized and characterized as an irreversible ligand for the phencyclidine (PCP)-binding site. It is the first chiral elec- trophilic affinity ligand for this site to have been described. This affinity ligand is based upon etoxadrol, a 1,3-dioxolane known to have PCP-like effects in vivo and in vitro. Etoxadrol-meta-isothiocyanate was found to be four-five times more potent in vitro than metaphit (1-[1-(3-isothiocyanatophenyl)cyclohexyl]pi~~dine), the only previously known electro- philic affinity ligand for the PCP-binding site. The binding was shown to be highly enantioselective for etoxadrol-meta- isothiocyanate (4a). The 2R,4R,6R-enantiomer of 4a was essentially inactive. The ability of the 2S,4$69enantiomer (4a) to interact with the benzodiazepine, muscarinic, and mu opioid receptor systems was also examined, and it was found not to interact with these receptor systems. It seems likely that 4a will prove to be a valuable tool in the study of structure and function of the PCP-binding site.
    [Show full text]
  • Sympathomimetic Anesthetics
    SYMPATHOMIMETIC ANESTHETICS GRAHAM CHEN, SC.D., M.D. A NEW TYPE of general anaesthetic drug has been developed in recent years. These drugs produce surgical anaesthesia without causing depression of respiratory and cardiovascular functions. Slight hypertension and taehycardia usually occur fol- lowing their intravenous administration. Mental confusion, dreaming, and a feel- ing of body dissociation are expressed by some individuals during the recovery period. Two classes of compounds containing a basic amine moiety have been shown to possess such properties: arylcycloalkylamines and 2-(2,2 substituted 1,3 dioxo- lan-4-yl) piperidines. Phencyelidine and ketamine belong to the first category, and dexoxadrol and etoxadrol to the latter. The structures of these drugs are shown in Figure 1. The anaesthetic and some other properties of the two classes of chemi- cals are remarkably similar; they may be considered together insofar as their principal pharmacologic actions are concerned. The purpose of this communication is to describe the neuropharmacological characteristics of these drugs, to indicate structure-activity relationships, and to discuss the mode of their anaesthetic actions. PHARMACOLOGY The progressive central effects of arylcycloalkylamines and 2-(2,2 substituted 1,3 dioxolan-4-yl) piperidines administered to animals in increasing doses gen- erally are excitation, ataxia, catalepsy, general anaesthesia and conwdsions. The degree of stimulation and depression varies with animal species and different compounds. Excitation is a prominent initial effect in rats and mice. It does not usually occur in primates, including man. 1- ~ Ataxia is a concomitant effect in rats and mice, and may occur in other species even in the absence of excitement.1 -3 Catalepsy, similar to that produced by bulbocapnine, is an outstanding central effect of these agents in all species including man.
    [Show full text]
  • The Joint French-US Seminar on Phencyclidine and Related
    TIPS deptember 1983 363 p-Amin&mmcacid 1 Dihydmplertdtns 1 Dihydmiok acid ’ J Lsym- I I 1 Dit-rfdrotolkacid ) I The joint French-US seminar on Tetrahydroblic acid phencyclidine and related arylcyclohexylamines Protein syllth8sis A joint French-US seminar was held at La (tram OH/N) one of the most potent opioid Grande Motte (Montpellier) France, 20-24 analgesics known. Removal of the oxygen September 1982, to assess the current sci- group in this series produces compounds entific status of phencyclidine (PCP) and with PCP-like activity to varying degrees. related arylcyclohexylamines. The seminar Zimmerman and associates (Lilly) reported L______--:-______I was attended by 58 scientists interested in the discovery and characterization of a new Fig. 5. Flow diagram of purim,thymidine and pro- the chemistry, biochemistry, pharmacol- series of benzo(f)isoquinoline derivatives rein synthesis. ogy, therapeutic applications and drug that have stimulus discriminative properties abuse aspects of arylcyclohexylamines. similar to PCP. One of the most potent is problems presented and the management of Thirty-four American, 19 French, 3 Japan the methylcyclopropyl bridged iso research show important differences, it is ese, 1 British and 1 Israeli investigator quinoline, LY 154045. PCP-like effects essential that industry continues to recruit attended, representing each of the above were maximized with a hydroxyl sub its proper proportion of the available talent. major disciplines. The organizing commit- stituent in the aromatic ring. Medawar has commented that the ordi- tee consisted of E. F. Domino of the Uni- One of the major questions in PCP nary processes of scientific discovery are versity of Michigan and P.
    [Show full text]
  • Sigma, PCP, and NMDA Receptors
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Sigma, PCP, and NMDA Receptors 133 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Sigma, PCP, and NMDA Receptors Editors: Errol B. De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse Doris Clouet, Ph.D. Division of Basic Research National Institute on Drug Abuse Edythe D. London, Ph.D. Addiction Research Center National Institute on Drug Abuse Research Monograph 133 1993 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Substance Abuse and Mental Health Services Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGMENT This monograph is based on the papers and discussions from a technical review on “Sigma, PCP, and NMDA Receptors Systems” held on September 27-28, 1989, in Baltimore, MD. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the Department of Health and Human Services.
    [Show full text]